APA (7th ed.) Citation

L, H., M, H., M, B., D, B., Z, C., M, P., . . . M, V. (2025). Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes. Clinical ophthalmology (Auckland, N.Z.), 19, 3729. https://doi.org/10.2147/OPTH.S543921

Chicago Style (17th ed.) Citation

L, Hejsek, Hrevuš M, Burova M, Beran D, Cyžová Z, Penčák M, Pařilová T, Liláková D, and Veith M. "Efficacy and Safety of Switching from Ranibizumab to Brolucizumab In Age-Related Macular Degeneration: Multicenter Real-World Outcomes." Clinical Ophthalmology (Auckland, N.Z.) 19 (2025): 3729. https://doi.org/10.2147/OPTH.S543921.

MLA (9th ed.) Citation

L, Hejsek, et al. "Efficacy and Safety of Switching from Ranibizumab to Brolucizumab In Age-Related Macular Degeneration: Multicenter Real-World Outcomes." Clinical Ophthalmology (Auckland, N.Z.), vol. 19, 2025, p. 3729, https://doi.org/10.2147/OPTH.S543921.